Bayer OA Knee Pain Pilot

NCT05349682 | Active Not Recruiting

• 1 other identifier: 00113621
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to investigate if MRI can be used to evaluated effect of knee artery embolization for knee osteoarthritis. Participants be evaluated in clinic, obtain a knee MRI, undergo embolization of the symptomatic knee, and follow up in clinic at 1, 6, and 12 months after embolization. A second MRI is obtained 6 months after embolization. Participants will keep a record of their pain level and treatment and answer questionnaires at each visit. In addition, this study aims to determine the effects of knee artery embolization on the amount of opioid (pain reliever drugs) needed to manage osteoarthritis-associated pain and change in quality of life.

Conditions

Osteoarthritis, Knee

Outcome Measures

Primary Outcomes (9)

• Change in enhancement time intensity curves obtained from CE-MRI

  To evaluate the effects of particle embolization on knee osteoarthritis progression using enhancement time intensity curves obtained from CE-MRI (Contrast Enhanced Magnetic Resonance Imaging)

  change from baseline at 6 month post procedure

• Change in Whole-Organ Magnetic Resonance Scoring (WORMS)

  To evaluate the effects of particle embolization on knee osteoarthritis progression using the WORMS scoring system. The higher the score, the worse the OA is. The scoring ranges from 0-332.

  change from baseline at 6 month post procedure

• Change in Multicenter Osteoarthritis Study (MOST) grading system for synovitis

  To evaluate the effects of particle embolization on knee osteoarthritis progression using the MOST grading system for synovitis. The higher the score, the worse the synovial inflammation is. The scoring ranges from 0-13. 0-4 normal or equivocal synovitis, 5-8 mild synovitis, 9-12 moderate synovitis, and 13 or greater is severe synovitis.

  change from baseline at 6 month post procedure

• Number of participants with 50% reduction in pain scores

  To determine the effects of geniculate artery embolization (GAE) on opioid requirements for managing OA associated pain. Assess pain using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Knee Injury and Osteoarthritis Outcome Score (KOOS). WOMAC is scored from 0-20 for pain, 0-8 for stiffness, and 0-68 for physical function. Higher scores indicate worse pain, stiffness, and function limitation. KOOS score is from 0-100, 0 being extreme problems and 100 being no problems.

  change from baseline at 1 month post procedure

• Number of participants with 50% reduction in pain scores

  To determine the effects of geniculate artery embolization (GAE) on opioid requirements for managing OA associated pain. Assess pain using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Knee Injury and Osteoarthritis Outcome Score (KOOS). WOMAC is scored from 0-20 for pain, 0-8 for stiffness, and 0-68 for physical function. Higher scores indicate worse pain, stiffness, and function limitation. KOOS score is from 0-100, 0 being extreme problems and 100 being no problems.

  change from baseline at 6 month post procedure

• Number of participants with 50% reduction in pain scores

  To determine the effects of geniculate artery embolization (GAE) on opioid requirements for managing OA associated pain. Assess pain using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Knee Injury and Osteoarthritis Outcome Score (KOOS). WOMAC is scored from 0-20 for pain, 0-8 for stiffness, and 0-68 for physical function. Higher scores indicate worse pain, stiffness, and function limitation. KOOS score is from 0-100, 0 being extreme problems and 100 being no problems.

  change from baseline at 12 month post procedure

• Incidence of adverse events associated with GAE

  The number of adverse events per participant

  1 month post procedure

• Incidence of adverse events associated with GAE

  The number of adverse events per participant

  6 month post procedure

• Incidence of adverse events associated with GAE

  The number of adverse events per participant

  12 month post procedure

Study Arms (1)

GAE and MRI treatment arm

EXPERIMENTAL

GAE is geniculate artery embolization.

Diagnostic Test: dynamic contrast enhanced MRI; Procedure: geniculate artery embolization

Interventions

dynamic contrast enhanced MRI DIAGNOSTIC_TEST

An MRI study of the knee will be done to check the degree of osteoarthritis and blood flow to the affected knee. This scan will take about 1-2 hour(s).

GAE and MRI treatment arm

geniculate artery embolization PROCEDURE

The physician will perform a diagnostic angiography, where they will take pictures of vessels near the knee that will be treated. Once the artery to be treated is identified, the doctor will guide a thin wire called a microwire, and a plastic tube called a microcatheter to the targeted artery, and more pictures of vessels at the knee will be taken. This picture will be used to see if there are any abnormal vessels at the knee, such as abnormal blood flow, abnormal vessel connections (between the veins and arteries), or new blood vessel growth. Once the targeted artery at the knee is confirmed, the doctor will inject enough particle embolic (Embozene) to slow or stop the blood flow in the geniculate artery. Once all vessels are treated, a final angiogram (pictures of blood vessels) will be performed to ensure that the blood flow has slowed.

GAE and MRI treatment arm

Eligibility Criteria

• Age: 25 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 25 to 90
• Symptomatic osteoarthritis of one or both knees, with Kellgren-Lawrence grade 1-3 assessed by weight-bearing knee radiography, including post-traumatic osteoarthritis
• One or more months of non-surgical therapy for knee pain such as joint injections, oral NSAIDs, or opioid analgesia
• Subjects able to provide informed consent. As this is a study of pain, patients must be able to consent for themselves.
• Patients without contraindication to MRI imaging with gadolinium-based contrast.

You may not qualify if:

• Anaphylaxis to gadolinium or iodinated contrast media
• Impaired renal function with GFR \<30ml/min
• Severe atherosclerotic disease of the lower extremity precluding percutaneous angiographic access to the involved geniculate artery(ies)
• Active septic arthritis of the symptomatic knee within 2 months of screening
• Malignancy of the involved knee
• Rheumatoid Arthritis or Gout
• Prior knee surgery
• Hemarthrosis
• Females who are pregnant or plan to become pregnant during the study. All participants able to become pregnant will be administered a urine pregnancy test.

Sponsors & Collaborators

• Medical University of South Carolina: lead
• Bayer: collaborator

Study Sites (1)

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

Dynamic Contrast Enhanced Magnetic Resonance Imaging

Condition Hierarchy (Ancestors)

Osteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases

Intervention Hierarchy (Ancestors)

Magnetic Resonance Imaging; Tomography; Diagnostic Imaging; Diagnostic Techniques and Procedures; Diagnosis

Study Officials

• Andre Uflacker, MD

  Medical University of South Carolina

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 28, 2022
• First Posted: April 27, 2022
• Study Start: October 1, 2022
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: April 2, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share
• Time Frame: duration of the study
• Access Criteria: The data will only be shared via encrypted email or encrypted cloud repository.

Locations

US (1)